Best deals to access real time data! |
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
SMALL CAP PRO
Monthly Subscription
for only
|
|
CHART Trader
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last: $ 72.49 ▲ 0.14 (0.19%) | |
| Company Name | Stock Ticker Symbol | Market | Type | ISIN | Company Description |
|---|---|---|---|---|---|
| Merck & Company (New) | MRK | NYSE | Ordinary Share |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| +0.14 | +0.19% | 72.35 | 72.655 | 71.935 | 72.3 | 72.21 | 16:00:22 |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 76,904 | 14,513,382 | $ 72.3181 | $ 1.05B | 6.65M | 52.83 - 72.89 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:29:34 | nxtday | 837,351 | $72.35 | USD |
| Industry Sector |
|---|
| Drug Manufacturers - Major |
Merck & Company (New) Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 192.42B | 2.66B | $ 2.39B | 0.88 | 77.70 | 2.69B |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ 1.92 | 2.65% | 09/14/2018 | -31.11k | 76.90% |
Merck & Company (New) News
Combo of Merck's Keytruda, Pfizer's Inlyta Meets Primary Endpoints Dow Jones News • Thu Oct 18, 2018 8:35 AM (2 days ago)
Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pfizer’s Inlyta® (axitinib) Significantly Improved Overall Surviv... Business Wire • Thu Oct 18, 2018 6:57 AM (2 days ago)
Merck Names Nike's Scholefield Chief Information, Digital Officer Dow Jones News • Wed Oct 17, 2018 7:34 AM (3 days ago)
Merck Announces Appointment of Jim Scholefield as Chief Information and Digital Officer Business Wire • Wed Oct 17, 2018 6:45 AM (3 days ago)
ADRs End Slightly Higher; AstraZeneca PLC, British American Tobacco and Novartis Trade Actively Dow Jones News • Tue Oct 16, 2018 5:28 PM (3 days ago)
U.S. FDA Grants LYNPARZA® (olaparib) Orphan Drug Designation for Pancreatic Cancer Business Wire • Tue Oct 16, 2018 6:30 AM (4 days ago)
FDA Gives Orphan Drug Status to AstraZeneca, Merck & Co.'s Lynparza Dow Jones News • Tue Oct 16, 2018 2:51 AM (4 days ago)
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRK Price Data
| Period † | Open | High | Low | VWAP | Min Vol | Max Vol | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|---|---|
| 1 Week | 68.7 | 72.655 | 68.42 | 70.9905 | 6M | 15M | 8M | 3.65 | 5.31% |
| 1 Month | 70.91 | 72.89 | 67.82 | 70.8949 | 4M | 16M | 8M | 1.44 | 2.03% |
| 3 Months | 62.45 | 72.89 | 62.3805 | 69.1450 | 4M | 17M | 8M | 9.9 | 15.85% |
| 6 Months | 58.86 | 72.89 | 56.255 | 64.1701 | 4M | 19M | 8M | 13.49 | 22.92% |
| 1 Year | 63.85 | 72.89 | 52.83 | 59.7302 | 4M | 48M | 10M | 8.5 | 13.31% |
| 3 Years | 52.35 | 72.89 | 47.97 | 59.5244 | 2M | 69M | 9M | 20 | 38.20% |
| 5 Years | 46.25 | 72.89 | 44.62 | 57.9539 | 2M | 69M | 10M | 26.1 | 56.43% |
Merck & Company (New) Description
| Merck & Co Inc is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. |
